Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Metformin and cancer: new applications for an old drug.

Kourelis TV, Siegel RD.

Med Oncol. 2012 Jun;29(2):1314-27. doi: 10.1007/s12032-011-9846-7. Epub 2011 Feb 8. Review.

PMID:
21301998
2.

Diabetes prevention programs.

Ramachandran A, Snehalatha C.

Med Clin North Am. 2011 Mar;95(2):353-72, viii. doi: 10.1016/j.mcna.2010.11.006. Review.

PMID:
21281838
3.

Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt.

Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S, Bumbasirevic V, Trajkovic V, Harhaji-Trajkovic L.

Eur J Pharmacol. 2011 Jan 25;651(1-3):41-50. doi: 10.1016/j.ejphar.2010.11.005. Epub 2010 Nov 27.

PMID:
21114978
4.

Metformin for aging and cancer prevention.

Anisimov VN.

Aging (Albany NY). 2010 Nov;2(11):760-74. Review.

5.

Clinical significance of molecular biomarkers in glioblastoma.

Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P.

Can J Neurol Sci. 2010 Sep;37(5):625-30.

PMID:
21059509
6.

Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.

Berezowska S, Diermeier-Daucher S, Brockhoff G, Busch R, Duyster J, Grosu AL, Schlegel J.

Int J Mol Med. 2010 Nov;26(5):713-21.

PMID:
20878094
7.

Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target.

Boyle JG, Salt IP, McKay GA.

Diabet Med. 2010 Oct;27(10):1097-106. doi: 10.1111/j.1464-5491.2010.03098.x. Review.

PMID:
20854376
8.

Metformin and other biguanides in oncology: advancing the research agenda.

Pollak M.

Cancer Prev Res (Phila). 2010 Sep;3(9):1060-5. doi: 10.1158/1940-6207.CAPR-10-0175. Epub 2010 Sep 1. Review.

9.

Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.

Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, Nakajima A.

Cancer Prev Res (Phila). 2010 Sep;3(9):1077-83. doi: 10.1158/1940-6207.CAPR-10-0186. Epub 2010 Sep 1.

10.

Metformin: taking away the candy for cancer?

Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG.

Eur J Cancer. 2010 Sep;46(13):2369-80. doi: 10.1016/j.ejca.2010.06.012. Epub 2010 Jul 23. Review.

PMID:
20656475
11.

An energetic tale of AMPK-independent effects of metformin.

Miller RA, Birnbaum MJ.

J Clin Invest. 2010 Jul;120(7):2267-70. doi: 10.1172/JCI43661. Epub 2010 Jun 23. Review.

12.

Metformin in cancer therapy: a new perspective for an old antidiabetic drug?

Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F.

Mol Cancer Ther. 2010 May;9(5):1092-9. doi: 10.1158/1535-7163.MCT-09-1186. Epub 2010 May 4. Review.

13.

AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.

Luo Z, Zang M, Guo W.

Future Oncol. 2010 Mar;6(3):457-70. doi: 10.2217/fon.09.174. Review.

14.

Metformin: a therapeutic opportunity in breast cancer.

Gonzalez-Angulo AM, Meric-Bernstam F.

Clin Cancer Res. 2010 Mar 15;16(6):1695-700. doi: 10.1158/1078-0432.CCR-09-1805. Epub 2010 Mar 9. Review.

15.

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.

Zakikhani M, Blouin MJ, Piura E, Pollak MN.

Breast Cancer Res Treat. 2010 Aug;123(1):271-9. doi: 10.1007/s10549-010-0763-9. Epub 2010 Feb 5.

PMID:
20135346
16.

AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas.

Guo D, Cloughesy TF, Radu CG, Mischel PS.

Cell Cycle. 2010 Jan 15;9(2):211-2. Epub 2010 Jan 6. No abstract available.

17.

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003053. doi: 10.1002/14651858.CD003053.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(1):CD003053.

PMID:
19821299
18.

Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy.

Riolfi M, Ferla R, Del Valle L, Piña-Oviedo S, Scolaro L, Micciolo R, Guidi M, Terrasi M, Cetto GL, Surmacz E.

Brain Pathol. 2010 Mar;20(2):481-9. doi: 10.1111/j.1750-3639.2009.00323.x. Epub 2009 Aug 6.

19.

The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.

Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12932-7. doi: 10.1073/pnas.0906606106. Epub 2009 Jul 22.

20.

STAT3 regulation of glioblastoma pathogenesis.

de la Iglesia N, Puram SV, Bonni A.

Curr Mol Med. 2009 Jun;9(5):580-90. Review.

Items per page

Supplemental Content

Write to the Help Desk